New Alzheimer’s Device Gains FDA Study Approval
The FDA authorized a clinical trial of the eShunt device to see if it helps clear neurotoxins in patients with Alzheimer's.
Updated on Oct. 31, 2026 in Alzheimer’s
Live Poll
Do you believe developing new, minimally invasive technologies is the best approach to treating Alzheimer's disease?
The FDA has granted an investigational device exemption for the eShunt System, a minimally invasive device designed to treat Alzheimer’s disease. CereVasc will now evaluate whether this technology can help patients manage the condition by improving brain health.
Why it matters
As the number of Americans with Alzheimer’s is expected to rise significantly, researchers are investigating new ways to address the disease. This trial explores if redirecting fluid can support the brain's natural ability to clear neurotoxins linked to cognitive decline.
The FDA granted an investigational device exemption to study the eShunt System in Alzheimer's patients, a population currently numbering 7.4 million Americans age 65 and older. While the device was previously studied for normal pressure hydrocephalus, its impact on Alzheimer’s is currently under investigation.
The players
CereVasc
A Massachusetts-based medical technology company focused on developing minimally invasive endovascular treatments for neurological conditions.
FDA
The U.S. federal agency responsible for regulating medical devices to ensure their safety and effectiveness for public use.
The details
The eShunt System is an endovascular device that uses a percutaneous transvenous-transdural approach to reach the central nervous system. By diverting cerebrospinal fluid into the venous system, the device is designed to enhance fluid cycling. This process aims to increase the clearance of neurotoxins that accumulate in the brain and are associated with Alzheimer's disease.
Timeline
2060 is the year by which the number of U.S. Alzheimer's patients is projected to reach 13.8 million.
Health Landscape
This development marks a shift in approach for CereVasc, moving from their prior focus in the STRIDE clinical trial for normal pressure hydrocephalus toward investigating neurodegenerative disease. It follows an evolving trend of testing mechanical drainage solutions to address chronic cognitive impairment.
This study is in the preliminary stages of human investigation, meaning the device is not currently available for routine clinical care. If you or a loved one are managing Alzheimer’s, it is worth discussing the status of emerging endovascular research with a neurologist.
The takeaway
The FDA’s approval of this study allows researchers to test whether improving cerebrospinal fluid cycling can clear neurotoxins in the brain. Patients and caregivers should stay informed by discussing current clinical trial eligibility with their primary neurologist.
Further reading
For more information on the current landscape of research and care, visit our guide on Alzheimer’s.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you believe developing new, minimally invasive technologies is the best approach to treating Alzheimer's disease?
